JP2017516828A5 - - Google Patents

Download PDF

Info

Publication number
JP2017516828A5
JP2017516828A5 JP2016571118A JP2016571118A JP2017516828A5 JP 2017516828 A5 JP2017516828 A5 JP 2017516828A5 JP 2016571118 A JP2016571118 A JP 2016571118A JP 2016571118 A JP2016571118 A JP 2016571118A JP 2017516828 A5 JP2017516828 A5 JP 2017516828A5
Authority
JP
Japan
Prior art keywords
methyl
pharmaceutically acceptable
acceptable salt
dione
quinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016571118A
Other languages
English (en)
Japanese (ja)
Other versions
JP6560257B2 (ja
JP2017516828A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/054173 external-priority patent/WO2015186062A1/en
Publication of JP2017516828A publication Critical patent/JP2017516828A/ja
Publication of JP2017516828A5 publication Critical patent/JP2017516828A5/ja
Application granted granted Critical
Publication of JP6560257B2 publication Critical patent/JP6560257B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016571118A 2014-06-03 2015-06-02 ピリミド[4,5−b]キノリン−4,5(3H,10H)−ジオン誘導体 Expired - Fee Related JP6560257B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14170974.1 2014-06-03
EP14170974 2014-06-03
PCT/IB2015/054173 WO2015186062A1 (en) 2014-06-03 2015-06-02 PYRIMIDO[4,5-b]QUINOLINE-4,5(3H,10H)-DIONE DERIVATIVES

Publications (3)

Publication Number Publication Date
JP2017516828A JP2017516828A (ja) 2017-06-22
JP2017516828A5 true JP2017516828A5 (enExample) 2018-06-28
JP6560257B2 JP6560257B2 (ja) 2019-08-14

Family

ID=50841688

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016571118A Expired - Fee Related JP6560257B2 (ja) 2014-06-03 2015-06-02 ピリミド[4,5−b]キノリン−4,5(3H,10H)−ジオン誘導体

Country Status (6)

Country Link
US (1) US9896448B2 (enExample)
EP (1) EP3152208B1 (enExample)
JP (1) JP6560257B2 (enExample)
CN (1) CN106459041B (enExample)
ES (1) ES2743184T3 (enExample)
WO (1) WO2015186062A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015186061A1 (en) 2014-06-03 2015-12-10 Novartis Ag Pyridopyrimidinedione derivatives
SG11201609209YA (en) 2014-06-03 2016-12-29 Novartis Ag Naphthyridinedione derivatives
WO2019225625A1 (ja) * 2018-05-23 2019-11-28 京都薬品工業株式会社 リードスルー誘導剤およびその医薬用途
WO2024194607A1 (en) * 2023-03-17 2024-09-26 Tay Therapeutics Limited Pyrimido[4,5-b][1,5]naphthyridine-4,5(3h,10h)-dione derivatives for the treatment of diseases associated with ptc mutations, such as e.g. cancer

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2884170B2 (ja) 1989-08-24 1999-04-19 株式会社フジモト・ブラザーズ 5−デアザフラビン系化合物を有効成分とする制癌剤
JP2989871B2 (ja) 1989-08-30 1999-12-13 大日本製薬株式会社 三環式化合物
JP2991382B2 (ja) * 1990-07-18 1999-12-20 大日本製薬株式会社 縮合三環式化合物およびその塩
US5908930A (en) 1995-03-15 1999-06-01 Pfizer Inc. 5,10-dihydropyrimdo 4,5-b!quinolin-4(1H)-one tyrosine kinase inhibitors
US6037345A (en) * 1998-01-13 2000-03-14 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazolinedione and pyridopyrimidinedione derivatives
US6468990B1 (en) * 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
WO2004006906A2 (en) 2002-07-15 2004-01-22 Combinatorx, Incorporated Methods for the treatment of neoplasms
EP1569645A2 (en) * 2002-12-12 2005-09-07 Pharmacia Corporation Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
PT3345895T (pt) 2003-04-11 2020-01-29 Ptc Therapeutics Inc Composto de ácido 1,2,4-oxadiazole benzóico e a sua utilização para a supressão sem sentido e tratamento de doenças
ES2594343T3 (es) 2006-04-03 2016-12-19 Technion Research & Development Foundation Limited Aminoglucósidos novedosos y usos de los mismos en el tratamiento de trastornos genéticos
WO2008024433A2 (en) 2006-08-23 2008-02-28 Neurogen Corporation Haloalkyl-substituted pyrimidinone derivatives
WO2008084236A1 (en) * 2007-01-11 2008-07-17 Astrazeneca Ab Chemical compounds 635 : pyridopyrimidinediones as pde4 inhibitors
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2422817A1 (en) 2010-07-29 2012-02-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Flavin-nucleic acid ligand conjugates
ES2710854T3 (es) * 2010-08-05 2019-04-29 Univ Lille Compuesto útil para el tratamiento de enfermedades mediadas por una mutación sin sentido y composición farmacéutica que comprende dicho compuesto
JP6076498B2 (ja) 2012-12-13 2017-02-08 ノバルティス アーゲー ナンセンス突然変異抑制剤としてのピリミド[4,5−b]キノリン−4,5(3h,10h)−ジオン
WO2015186061A1 (en) 2014-06-03 2015-12-10 Novartis Ag Pyridopyrimidinedione derivatives
SG11201609209YA (en) * 2014-06-03 2016-12-29 Novartis Ag Naphthyridinedione derivatives

Similar Documents

Publication Publication Date Title
JP2018021046A5 (enExample)
JP2016534063A5 (enExample)
JP2016040288A5 (enExample)
JP2019521988A5 (enExample)
NZ723271A (en) Fused imidazole derivatives useful as ido inhibitors
EP4420679A3 (en) Lipids and lipid nanoparticle formulations for delivery of nucleic acids
JP2015537020A5 (enExample)
RU2018106453A (ru) Соединения
JP2014502641A5 (enExample)
JP2016515628A5 (enExample)
RU2014135436A (ru) Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
RU2017134443A (ru) Способ лечения с применением традипитанта
JP2017516828A5 (enExample)
JP2016516773A5 (enExample)
JP2015512432A5 (enExample)
JP2015521617A5 (enExample)
JP2017513809A5 (enExample)
RU2013150861A (ru) Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
JP2016529285A5 (enExample)
JP2015528501A5 (enExample)
JP2014515407A5 (enExample)
JPWO2022250170A5 (enExample)
JP2017516829A5 (enExample)
JP2018522927A5 (enExample)